Litcius/Paper detail

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

Brett Hughes, E. Munoz-Couselo, Laurent Mortier, Å. Bratland, Ralf Gutzmer, Osama Roshdy, René González Mendoza, Jacob Schachter, Ana Arance, Florent Grange, Nicolás Meyer, Abhishek Joshi, Salem Billan, P. Zhang, B. Gumuscu, Ramona F. Swaby, Jean‐Jacques Grob

2021Annals of Oncology201 citationsDOI

Topics & Concepts

MedicinePembrolizumabTolerabilityInterquartile rangeInternal medicineCohortClinical endpointResponse Evaluation Criteria in Solid TumorsPhases of clinical researchSurgeryOncologyAdverse effectGastroenterologyClinical trialCancerImmunotherapyNonmelanoma Skin Cancer StudiesCutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers